[CAS NO. 428863-50-7] Certolizumab pegol

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-P9953
Brand:	MCE
CAS:	428863-50-7

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Certolizumab]

For research use only. We do not sell to patients.

Summary

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α ( TNF-α ). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research ^[1] ^[2] .

In Vitro

Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC ₉₀ of 3 ng/mL ^[2] .
Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes ^[2] .
Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) ^[2] .
Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals) ^[3]
Dosage:	10 μg
Administration:	Intraperitoneal administration, single dose
Result:	Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01295151	Julia Brown\|University of Leeds	Rheumatoid Arthritis	August 2011	Phase 4
NCT01098201	University of Rochester	Rheumatoid Arthritis	October 2010
NCT01374971	Nathan Wei, MD, FACP, FACR:\|University of California, San Diego\|Arthritis Treatment Center, Maryland	Rheumatoid Arthritis	September 2011	Phase 3
NCT01582568	Baylor College of Medicine\|UCB Pharma	Crohns Disease	June 2011
NCT03100253	Mario Negri Institute for Pharmacological Research	Rheumatoid Arthritis	March 1, 2018	Phase 4
NCT00993317	Korea Otsuka Pharmaceutical Co., Ltd.	Rheumatoid Arthritis	October 2009	Phase 3
NCT03955861	Belfast Health and Social Care Trust\|British Medical Association\|Psoriasis and Psoriatic Arthritis Alliance\|Queen´s University, Belfast	Psoriatic Arthritis\|Psoriasis\|Enthesitis	February 14, 2019
NCT00845663	UCB Pharma	Healthy	October 2007	Phase 1
NCT02326298	UCB Biopharma S.P.R.L.\|UCB Pharma	Psoriasis\|Plaque Psoriasis	December 16, 2014	Phase 3
NCT03293784	Institut Claudius Regaud	Melanoma	October 16, 2017	Phase 1
NCT02132234	Jagiellonian University\|Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland	Rheumatoid Arthritis\|Psoriatic Arthritis\|Ankylosing Spondylitis\|Hypertension	June 2013	Phase 4
NCT01255761	UCB Pharma	Rheumatoid Arthritis	November 2010	Phase 4
NCT00851318	Astellas Pharma Inc\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	March 2009	Phase 3
NCT00329420	UCB Pharma	Crohn´s Disease	May 2006	Phase 2
NCT00544154	UCB Pharma	Arthritis, Rheumatoid	October 2002	Phase 3
NCT03559660	UCB Biopharma S.P.R.L.\|UCB Pharma	Crohn´s Disease
NCT02073526	Oslo University Hospital	Inflammatory Bowel Disease\|Crohn´s Disease\|Ulcerative Colitis	May 2013
NCT00674362	UCB Pharma	Rheumatoid Arthritis	June 2008	Phase 3
NCT02552212	UCB BIOSCIENCES GmbH\|UCB Pharma	Axial Spondyloarthritis\|Nonradiographic Axial Spondyloarthritis\|Nr-axSpA	September 2015	Phase 3
NCT04569890	RenJi Hospital	Rheumatoid Arthritis\|Pregnancy Related	December 1, 2020	Not Applicable
NCT02497976	ICStudy, LLC\|UCB Pharma	Cystitis, Interstitial	December 15, 2015	Phase 3
NCT02714881	Brigham and Women´s Hospital	Rheumatoid Arthritis\|Cardiovascular Disease	April 2016	Not Applicable
NCT00160602	UCB Pharma	Rheumatoid Arthritis	June 2005	Phase 3
NCT00307931	UCB Pharma	Crohn´s Disease	April 2007	Phase 3
NCT02154425	UCB BIOSCIENCES, Inc.\|PPD\|Parexel\|UCB Pharma	Axial Spondyloarthritis (AxSpA)\|Non-radiographic Evidence-AxSpA\|Ankylosing Spondylitis\|Crohn´s Disease\|Psoriatic Arthritis\|Rheumatoid Arthritis	September 2014	Phase 1
NCT00791921	Otsuka Pharmaceutical Co., Ltd.\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	November 2008	Phase 3
NCT02319642	UCB Pharma SA\|Parexel\|UCB Pharma	Rheumatoid Arthritis	November 2014	Phase 3
NCT00791999	Otsuka Pharmaceutical Co., Ltd.\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	November 2008	Phase 2\|Phase 3
NCT01197066	Korea Otsuka Pharmaceutical Co., Ltd.	Rheumatoid Arthritis	March 2010	Phase 3
NCT00349752	UCB Pharma	Crohn´s Disease	November 2006	Phase 3
NCT00329550	UCB Japan Co. Ltd.\|UCB Pharma	Crohn´s Disease	May 2006	Phase 2
NCT00329303	UCB Pharma	Psoriasis	April 2006	Phase 2
NCT01817972	Gastroenterology Research of America\|UCB Pharma	Crohn´s Disease	March 2013	Phase 3
NCT01521923	UCB Pharma	Rheumatoid Arthritis	January 2012	Phase 3
NCT04725422	Seattle Children´s Hospital\|Boston Children´s Hospital, Boston, MA, USA\|Hospital for Special Surgery, New York City, NY, USA\|Joseph M Sanzari Children´s Hospital, Hackensack University Medical Center, Hackensack, NJ, USA\|Riley Children´s Hospital, Indianapolis, IN, USA\|University of North Carolina, Chapel Hill, NC, USA\|Royal Children´s Hospital, Melbourne, Australia\|Hacettepe University, Ankara, Turkey\|Bambino Gesù Children´s Hospital, Rome, Italy\|University of British Columbia, Vancouver, BC, Canada\|Meyer Children´s Hospital, Florence, Italy\|Mansoura University	Chronic Nonbacterial Osteomyelitis\|Chronic Recurrent Multifocal Osteomyelitis	August 1, 2018
NCT02019602	UCB BIOSCIENCES, Inc.\|PPD\|Parexel\|UCB Pharma	Axial Spondyloarthritis (AxSpA)\|Non-radiographic Evidence-AxSpA\|Ankylosing Spondylitis\|Crohn´s Disease\|Psoriatic Arthritis\|Rheumatoid Arthritis	January 2014	Phase 1
NCT00850343	Astellas Pharma Inc\|UCB Japan Co. Ltd.	Rheumatoid Arthritis	March 2009	Phase 3
NCT00356408	UCB Pharma	Crohn´s Disease	January 2007	Phase 3
NCT00245765	UCB Pharma	Chronic Plaque Psoriasis	October 2005	Phase 2
NCT03020992	UCB Biopharma SRL\|UCB Pharma	Axial Spondyloarthritis (axSpA)\|Anterior Uveitis (AU)	December 21, 2016	Phase 4
NCT00308581	UCB Pharma	Crohn´s Disease	April 2006	Phase 3
NCT01550003	UCB BIOSCIENCES GmbH\|PRA Health Sciences\|UCB Pharma	Polyarticular-course Juvenile Idiopathic Arthritis (JIA)	March 8, 2012	Phase 3
NCT00160693	UCB Pharma	Rheumatoid Arthritis	March 2003	Phase 3
NCT00297648	UCB Pharma	Crohn´s Disease	February 2006	Phase 3
NCT01091220	UCB Pharma	Sperm Quality	March 2010	Phase 1
NCT00548834	UCB Pharma	Rheumatoid Arthritis	June 2003	Phase 3
NCT02293590	Rüdiger B. Müller\|UCB Pharma\|Cantonal Hospital of St. Gallen	Rheumatoid Arthritis	November 2013	Phase 2
NCT00843778	UCB Pharma	Rheumatoid Arthritis	January 2009	Phase 3
NCT01053559	Shafran Gastroenterology Center\|UCB Pharma	Crohn´s Disease	January 2010	Not Applicable
NCT01292265	UCB Pharma	Rheumatoid Arthritis	February 2011	Phase 3
NCT00717236	UCB Pharma	Rheumatoid Arthritis	July 2008	Phase 3
NCT00152425	UCB Pharma	Crohn´s Disease	February 2004	Phase 3
NCT01443364	UCB Italy s.p.a.\|UCB Pharma	Rheumatoid Arthritis	December 2011	Phase 4
NCT00291668	UCB Pharma	Crohn´s Disease	March 2, 2006	Phase 2
NCT00152490	UCB Pharma	Crohn´s Disease	December 2003	Phase 3
NCT02451748	University of Illinois at Chicago\|UCB Pharma	Rheumatoid Arthritis	August 2015	Phase 4
NCT00333788	UCB Pharma	Crohn´s Disease	October 2006	Phase 3
NCT00160524	UCB Pharma SA\|UCB Pharma	Crohn´s Disease	July 2004	Phase 3
NCT04610476	University of Erlangen-Nürnberg Medical School	Psoriatic Arthritis\|Withdrawal\|Reduction	October 19, 2020	Phase 3
NCT02430909	UCB Celltech\|PRA Health Sciences\|UCB Pharma	Rheumatoid Arthritis	April 2015	Phase 2
NCT01519791	UCB Pharma SA\|UCB Pharma	Rheumatoid Arthritis	January 2012	Phase 3
NCT02365948	UCB Pharma SA\|Parexel\|UCB Pharma	Healthy Subjects	March 2015	Phase 1
NCT03215277	UCB Biopharma S.P.R.L.\|UCB Pharma	Ankylosing Spondylitis	October 4, 2017	Phase 2
NCT04991025	Memorial Sloan Kettering Cancer Center	Lung Cancer\|Lung Cancer Stage II\|Lung Cancer Stage III	October 19, 2022	Phase 2
NCT00580840	UCB Pharma	Rheumatoid Arthritis	December 2007	Phase 4
NCT03559686	UCB Biopharma S.P.R.L.\|UCB Pharma	Rheumatoid Arthritis
NCT02120807	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Stage IV Lung Adenocarcinoma	April 2014	Phase 1
NCT01864265	University of Erlangen-Nürnberg Medical School	Rheumatoid Arthritis	July 2013	Phase 3
NCT02586246	Astellas Pharma Inc\|UCB Japan Co. Ltd.	Active Rheumatoid Arthritis	January 2011	Phase 3
NCT02326272	UCB Biopharma S.P.R.L.\|UCB Pharma	Psoriasis\|Plaque Psoriasis	December 15, 2014	Phase 3
NCT03152058	David Ware Branch\|Hospital for Special Surgery, New York\|University of Toronto\|NYU Langone Health\|University of Utah	High Risk Pregnancy\|Pregnancy Complications\|Antiphospholipid Syndrome in Pregnancy\|Lupus Anticoagulant Disorder	May 17, 2017	Phase 2
NCT01235598	UCB Pharma	Rheumatoid Arthritis	December 2010	Phase 3
NCT04163016	UCB Biopharma S.P.R.L.\|UCB Pharma	Rheumatoid Arthritis\|Psoriatic Arthritis\|Crohn´s Disease\|Axial Spondyloarthritis\|Plaque Psoriasis	June 19, 2020	Phase 1
NCT01500278	UCB Pharma SA\|Parexel\|UCB Pharma	Rheumatoid Arthritis	December 2011	Phase 4
NCT00358683	UCB Pharma	Crohn´s Disease	November 2007	Phase 3
NCT00160706	UCB Pharma SA\|UCB Pharma	Crohn´s Disease	February 2004	Phase 3
NCT00993668	UCB Pharma	Rheumatoid Arthritis	September 2009	Phase 4
NCT00552058	UCB Pharma	Crohn Disease	March 2008	Phase 3
NCT00899678	UCB Celltech\|UCB Pharma	Crohn´s Disease	April 2009	Phase 2
NCT00753454	UCB Pharma	Rheumatoid Arthritis	September 2008	Phase 3
NCT04053881	UCB Biopharma SRL\|UCB Pharma	Plaque Psoriasis	August 21, 2019
NCT03016260	TcLand Expression S.A.\|European Commission	RheumatoId Arthritis	December 2016
NCT02151851	UCB Pharma SA, Belgium\|Parexel\|UCB Pharma	Rheumatoid Arthritis	July 2014	Phase 3
NCT01190410	UCB Pharma	Crohn´s Disease	August 2010	Phase 2
NCT02597829	Shafran Gastroenterology Center\|UCB Pharma	Crohn´s Disease	November 2015	Phase 4
NCT00152386	UCB Pharma	Rheumatoid Arthritis	February 2005	Phase 3
NCT00354367	UCB Pharma	Crohn Disease	January 2007	Phase 3
NCT01024647	Atlanta Gastroenterology Associates\|UCB Pharma	Crohn´s Disease	December 2009	Phase 4
NCT01213017	Oklahoma Medical Research Foundation\|UCB Pharma	Rheumatoid Arthritis	September 2010	Phase 3
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT00160641	UCB Pharma	Rheumatoid Arthritis	November 2005	Phase 3
NCT04123795	UCB Biopharma SRL\|UCB Pharma	Moderate Chronic Plaque Psoriasis\|Severe Chronic Plaque Psoriasis\|Mixed Guttate+Plaque Psoriasis	January 21, 2020	Phase 3
NCT04740814	UCB Biopharma SRL\|UCB Pharma	Rheumatoid Arthritis	February 11, 2021	Phase 1
NCT02505542	UCB BIOSCIENCES GmbH\|Parexel\|UCB Pharma	Axial Spondyloarthrithis\|Ankylosing Spondylitis	July 2015	Phase 3
NCT02346240	UCB Biopharma S.P.R.L.\|UCB Pharma	Psoriasis\|Plaque Psoriasis	February 11, 2015	Phase 3
NCT00175877	UCB Pharma	Rheumatoid Arthritis	June 2005	Phase 3
NCT00813774	UCB Pharma	Bioavailability Study on Healthy Volunteers	February 2008	Phase 1
NCT03051217	UCB Biopharma S.P.R.L.\|UCB Pharma	Moderate to Severe Psoriasis\|Generalized Pustular Psoriasis and Erythrodermic Psoriasis	February 21, 2017	Phase 2\|Phase 3
NCT04643483	UCB Biopharma SRL\|UCB Pharma	Crohn´s Disease	June 2021	Phase 3

Appearance

Liquid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97.
[2] Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.
[3] Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. Pancreas. 2016 Sep;45(8):1120-5.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart